Abstract

P-253 - A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
Francesca Battaglin ... Sara Lonardi
BMC Cancer | VOL. 18
Francesca Battaglin, et. al.Francesca Battaglin ... Sara Lonardi
25 Jan 2018
<p>The impact of panitumumab treatment on survival and quality of life in patients with <em>RAS</em> wild-type metastatic colorectal cancer</p>
Francesca Battaglin ... Alberto Puccini
Cancer Management and Research | VOL. Volume 11
Francesca Battaglin, et. al.Francesca Battaglin ... Alberto Puccini
01 Jun 2019
Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis.
Lola-Jade Palmieri ... Veronika Veskrnova
Cancers | VOL. 14
Lola-Jade Palmieri, et. al.Lola-Jade Palmieri ... Veronika Veskrnova
10 Mar 2022
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
... Matthew Burge
BMC Cancer | VOL. 21
, et. al. ... Matthew Burge
18 Aug 2021
View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title
Journal
Date
Author
Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes
P Tarantino ... S M Tolaney
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
P Tarantino, et. al.P Tarantino ... S M Tolaney
01 Jul 2024
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia
B Eichhorst ... C Buske
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
B Eichhorst, et. al.B Eichhorst ... C Buske
01 Jul 2024
Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer
M Cecchini ... R Sundar
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
M Cecchini, et. al.M Cecchini ... R Sundar
01 Jul 2024
Table of Contents
-
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
--
01 Jul 2024
View more papers